Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.

Autor: Silva, Manuel A.¹ (AUTHOR) manuel_agustin.silva_munoz@boehringer-ingelheim.com, Williams, Shuntae² (AUTHOR), Hauert, Sylvie² (AUTHOR), Ovadia, Benjamin³ (AUTHOR), Gupta, Indu³ (AUTHOR), Waldmeier, Lorenz⁴ (AUTHOR), Jaimes, Yarúa¹ (AUTHOR), Al-Masri, Hytham² (AUTHOR)

Publikováno v: PLoS ONE. 11/4/2024, Vol. 19 Issue 11, p1-13. 13p.

ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.

Autor: Ghaderi A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Daneshmanesh AH; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Moshfegh A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Kokhaei P; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Immunology, Semnan University of Medical Sciences, Semnan 35147-99442, Iran., Vågberg J; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Schultz J; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Olin T; Kancera AB, Karolinska Institute Science Park, 171 48 Solna, Sweden., Harrysson S; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Smedby KE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Drakos E; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Pathology, Medical School, University of Crete, 71110 Heraklion Crete, Greece., Rassidakis GZ; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Österborg A; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, 171 77 Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institutet, 17164 Stockholm, Sweden.

Publikováno v: Biomedicines [Biomedicines] 2020 Jun 23; Vol. 8 (6). Date of Electronic Publication: 2020 Jun 23.

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Autor: Daneshmanesh AH; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Ghaderi A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Moshfegh A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hansson L; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Schultz J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Vågberg J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Byström S; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olsson E; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olin T; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Österborg A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.

Publikováno v: PloS one [PLoS One] 2018 Jun 01; Vol. 13 (6), pp. e0198038. Date of Electronic Publication: 2018 Jun 01 (Print Publication: 2018).

Recent advances of benzimidazole as anticancer agents.

Autor: Venugopal, Sneha¹ (AUTHOR), Kaur, Balwinder¹ (AUTHOR), Verma, Anil¹ (AUTHOR), Wadhwa, Pankaj¹ (AUTHOR) pankajwadhwadhwa88@gmail.com, Magan, Muskan¹ (AUTHOR), Hudda, Sharwan¹ (AUTHOR), Kakoty, Violina¹ (AUTHOR)

Publikováno v: Chemical Biology & Drug Design. Aug2023, Vol. 102 Issue 2, p357-376. 20p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.